BlackRock’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-13,385,970
Closed -$1.14B 5269
2020
Q3
$1.14B Sell
13,385,970
-728,256
-5% -$36.8M 0.04% 413
2020
Q2
$500M Sell
14,114,226
-1,663,667
-11% -$48.6M 0.02% 711
2020
Q1
$213M Buy
15,777,893
+1,081,297
+7% +$18.2M 0.01% 1119
2019
Q4
$311M Buy
14,696,596
+460,527
+3% +$8.12M 0.01% 1160
2019
Q3
$189M Buy
14,236,069
+437,266
+3% +$6.43M 0.01% 1445
2019
Q2
$191M Buy
13,798,803
+1,239,462
+10% +$18.7M 0.01% 1468
2019
Q1
$241M Sell
12,559,341
-80,009
-0.6% -$1.29M 0.01% 1268
2018
Q4
$180M Buy
12,639,350
+435,568
+4% +$8.65M 0.01% 1397
2018
Q3
$254M Buy
12,203,782
+974,954
+9% +$23.1M 0.01% 1293
2018
Q2
$266M Buy
11,228,828
+2,195,066
+24% +$44.1M 0.01% 1232
2018
Q1
$132M Sell
9,033,762
-30,497
-0.3% -$498K 0.01% 1649
2017
Q4
$146M Buy
9,064,259
+736,608
+9% +$8.69M 0.01% 1602
2017
Q3
$116M Buy
8,327,651
+95,208
+1% +$949K 0.01% 1752
2017
Q2
$72.7M Buy
8,232,443
+315,950
+4% +$2.22M ﹤0.01% 2005
2017
Q1
$51.2M Buy
7,916,493
+7,907,956
+92,632% +$40.1M ﹤0.01% 2202
2016
Q4
$32K Sell
8,537
-93
-1% -$275 ﹤0.01% 3117
2016
Q3
$28K Hold
8,630
﹤0.01% 3207
2016
Q2
$20K Buy
8,630
+3,141
+57% +$10.5K ﹤0.01% 3270
2016
Q1
$14K Buy
5,489
+3,644
+198% +$8.2K ﹤0.01% 3021
2015
Q4
$6K Hold
1,845
﹤0.01% 3109
2015
Q3
$3K Hold
1,845
﹤0.01% 3134
2015
Q2
$7K Sell
1,845
-370
-17% -$1.51K ﹤0.01% 3018
2015
Q1
$8K Hold
2,215
﹤0.01% 2870
2014
Q4
$11K Hold
2,215
﹤0.01% 2731
2014
Q3
$8K Hold
2,215
﹤0.01% 2883
2014
Q2
$8K Buy
2,215
+141
+7% +$518 ﹤0.01% 2954
2014
Q1
$9K Hold
2,074
﹤0.01% 2807
2013
Q4
$10K Hold
2,074
﹤0.01% 2736
2013
Q3
$13K Hold
2,074
﹤0.01% 2506
2013
Q2
$11K Buy
+2,074
New +$6.81K ﹤0.01% 2609

BlackRock's IMMU Position: Q4 2020 in Review

BlackRock sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 13,385,970 shares — an estimated $1.14B sold.

BlackRock first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $1.14B in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • BlackRock reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • BlackRock sold 13,385,970 Immunomedics Inc shares in Q4 2020, an estimated $1.14B.
  • BlackRock first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
  • BlackRock's Immunomedics Inc position peaked at $1.14B in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on BlackRock's 13F filing for Q4 2020, filed 5 Feb 2021.